Addition of 3‐methoxytyramine or chromogranin A to plasma free metanephrines as the initial test for pheochromocytoma and paraganglioma: Which is the best diagnostic strategy

Measurements of plasma free metanephrines (MNs), including MN and normetanephrine, provide high sensitivity and specificity for the diagnosis of pheochromocytoma and paraganglioma (PPGL). 3‐Methoxytyramine (3‐MT) and chromogranin A (CgA) may allow the detection of dopamine‐producing or biochemically silent PPGL. The aim of this study was to evaluate whether measurements of plasma 3‐MT or CgA as a supplement of plasma MNs offer a better diagnostic strategy for initial testing of PPGL.

[1]  F. Beuschlein,et al.  Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma , 2020, Clinical chemistry and laboratory medicine.

[2]  T. Zelinka,et al.  Chromogranin A in the Laboratory Diagnosis of Pheochromocytoma and Paraganglioma , 2019, Cancers.

[3]  F. Beuschlein,et al.  Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[4]  F. Beuschlein,et al.  Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. , 2018, Clinical chemistry.

[5]  J. Burgess,et al.  ANNALS EXPRESS: Clinical utility of chromogranin A for surveillance of succinate dehydrogenase B- and D-related paraganglioma: , 2018 .

[6]  T. Zelinka,et al.  Radioimmunoassay of chromogranin A and free metanephrines in diagnosis of pheochromocytoma. , 2017, Physiological research.

[7]  J. Lenders,et al.  Update on Modern Management of Pheochromocytoma and Paraganglioma , 2017, Endocrinology and metabolism.

[8]  F. Beuschlein,et al.  Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma , 2017, European journal of endocrinology.

[9]  O. Dekkers,et al.  European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma. , 2016, European journal of endocrinology.

[10]  W. Young,et al.  Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. , 2014, The Journal of clinical endocrinology and metabolism.

[11]  K. Pacak,et al.  Clinical utility of chromogranin A in SDHx‐related paragangliomas , 2014, European journal of clinical investigation.

[12]  J. Romijn,et al.  Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. , 2013, European journal of endocrinology.

[13]  K. Mann,et al.  Plasma and Urinary Metanephrines Determined by an Enzyme Immunoassay, but not Serum Chromogranin A for the Diagnosis of Pheochromocytoma in Patients with Adrenal Mass , 2012, Experimental and Clinical Endocrinology & Diabetes (Barth).

[14]  N. Martin,et al.  Quantifying the effects of renal impairment on plasma concentrations of the neuroendocrine neoplasia biomarkers chromogranin A, chromogranin B, and cocaine- and amphetamine-regulated transcript. , 2012, Clinical chemistry.

[15]  L. Hofbauer,et al.  Measurements of plasma methoxytyramine, normetanephrine, and metanephrine as discriminators of different hereditary forms of pheochromocytoma. , 2011, Clinical chemistry.

[16]  J. Romijn,et al.  Plasma chromogranin A levels are increased in a small portion of patients with hereditary head and neck paragangliomas , 2011, Clinical endocrinology.

[17]  Erin E. Chambers,et al.  Performance of plasma free metanephrines measured by liquid chromatography-tandem mass spectrometry in the diagnosis of pheochromocytoma. , 2010, Clinica chimica acta; international journal of clinical chemistry.

[18]  M. Merino,et al.  Biochemically silent abdominal paragangliomas in patients with mutations in the succinate dehydrogenase subunit B gene. , 2008, The Journal of clinical endocrinology and metabolism.

[19]  P. Igaz,et al.  Marked chromogranin A elevation in a patient with bilateral adrenal incidentalomas, and its rapid normalization after discontinuation of proton pump inhibitor therapy , 2007, Clinical endocrinology.

[20]  L. Ceriani,et al.  Chromogranin A immunoradiometric assay in diagnosis of pheochromocytoma: comparison with plasma metanephrines and 123I-MIBG scan. , 2006, The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of....

[21]  M. Boniardi,et al.  The role of chromogranin A in the management of patients with phaeochromocytoma , 2006, Clinical endocrinology.

[22]  M. Ferdeghini,et al.  A new human chromogranin 'A' immunoradiometric assay for the diagnosis of neuroendocrine tumours , 2001, British Journal of Cancer.

[23]  W. Young,et al.  Plasma chromogranin A or urine fractionated metanephrines follow-up testing improves the diagnostic accuracy of plasma fractionated metanephrines for pheochromocytoma. , 2008, The Journal of clinical endocrinology and metabolism.